[Japon] Can Japan bridge the vaccine divide?
Auteur : Shihoko Goto. Contributing writer of The Japan Times. Shihoko Goto is deputy director for geoeconomics with the Wilson Center’s Asia Program based in Washington.
Production : The Japan Times
Diffusion : site de The Japan Times
Date : 18 novembre 2020
As winter approaches and colder weather makes it even more difficult to adhere to social distancing measures, the odds of COVID-19 spreading still further seem to be inevitable. Still, despite having the highest infection rate in the world, there is growing optimism in the United States, thanks to the prospect of effective vaccines being developed in the not-too-distant future. The fact that financial markets worldwide have also welcomed the latest news from Pfizer and Moderna on their respective developments for fighting the virus also demonstrates continued global confidence in U.S. scientific research.
Source : Shihoko Goto, « Can Japan bridge the vaccine divide? », The Japan Times, 18/11/2020. URL : https://www.japantimes.co.jp/opinion/2020/11/18/commentary/japan-commentary/japan-coronavirus-vaccine-divide/ (consulté le 18/11/2020)
Photo « à la une » : Japan too has been developing its own drug, Avigan, against COVID-19. Yet the drug being developed by Fujifilm is not a vaccine but rather a treatment for coronavirus symptoms. © BLOOMBERG